Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market

Analysts initiated coverage with Buy ratings on SpaceX, Securitize ; Overweight on Londian Wason.

Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular se

Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).

HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on NeuroSense Therapeutic

Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-co

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by a

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE,

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-

Notifications have no immediate effect on the listing or trading of the Company's securities on 

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed th

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnolo

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

NeuroSense Therapeutics Ltd. ("NeuroSense") today announced that the database has been locke

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, w

NeuroSense Therapeutics Ltd. (the "Company") Reports Additional Clinical Data from its Phase

Financing at 40% premium to market price provides near-term bridge to anticipated milestonesCAMBRIDG

NeuroSense Therapeutics Ltd. today announced a new analysis of 18-month data from its Phase 2b PARAD

https://www.sec.gov/Archives/edgar/data/1875091/000121390025078783/ea0254016-6k_neurosense.htm

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy

NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canad

D. Boral Capital analyst Jason Kolbert initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN

NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Com

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway a

New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinica

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.54) per share which beat the

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout,

In connection with the offering, NeuroSense agreed to sell an aggregate of 4,000,000 ordinary shares

NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial desi

Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026Estimated potential m